International Stem Cell Corporation Blog

PRWEB: Absorption Systems Expands In Vivo Drug and Medical Device Testing Capabilities

2012-02-01T08:18:00.000-08:00

Preclinical contract research organization renovates facility, adding state-of-the-art technology and upgrading ocular testing services.

Exton, PA (PRWEB) January 31, 2012

Absorption Systems announces the latest in a series of milestones in the continuing expansion of its AAALAC-accredited and GLP-compliant facility in San Diego, CA. The facility is undergoing extensive renovations to upgrade and expand the company’s in vivo testing capabilities for drugs and medical devices, including the construction of a dedicated ocular testing laboratory with state-of-the-art equipment, including a Heidelberg Spectralis® optical coherence tomography (OCT) unit. This instrument produces detailed digital images of the retina, enabling precise monitoring of the efficacy and toxicity of drugs and medical devices. Absorption Systems’ San Diego facility, in the midst of a major expansion of staff, equipment, and capabilities in the specialized area of preclinical ocular drug and device testing, continues to see significant growth year-over-year early in 2012.

Glenwood Gum, M.S., Ph.D., who joined Absorption Systems in 2011 as Associate Director, Preclinical Studies, commented, “This OCT technology gives a huge boost to our ocular testing capabilities, which will immediately benefit our rapidly expanding client base.” Dr. Gum is an expert in preclinical ocular studies, having developed or co-developed many of the preclinical models of glaucoma, age-related macular degeneration (AMD), retinoblastoma, uveitis, and diabetic retinopathy that are used all over the world for drug testing. His expertise, along with dedicated staff and the addition of state-of-the-art equipment and facilities, are key to Absorption Systems’ strategy to aggressively pursue new business opportunities in the preclinical ocular testing arena.

Dr. Gum will be a featured speaker on Preclinical Glaucoma and CNV Models at the 4th Ocular Diseases and Drug Discovery conference in Las Vegas, NV February 27-28, 2012.

Patrick Dentinger, President and CEO of Absorption Systems, said, “For Absorption Systems, being a market leader in whatever endeavor we pursue is a cornerstone of our business philosophy. This requires scientific expertise, state-of-the-art equipment and facilities, and access to emerging technologies. These factors, combined with Absorption Systems’ customer-centric approach, make our commitment to being a top-tier ocular service provider a reality in 2012.”

Absorption Systems’ preclinical ocular test portfolio includes in vivo ocular pharmacokinetics, efficacy, and safety in multiple species, as well as in vitro ocular permeability and metabolism. For example, the human corneal orb is a unique in vitro permeability model available as a service platform only through Absorption Systems. The corneal orb, cultured from human pluripotent stem cells, was developed by Lifeline Cell Technology, Inc., a wholly-owned subsidiary of International Stem Cell Corporation, and has been validated by Absorption Systems as an in vitro corneal permeability test system.

About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit http://www.absorption.com.

SOURCE: http://www.prweb.com/releases/2012/1/prweb9153045.htm

International Stem Cell Corporation - "How Is Parthenogenesis Done?"

2011-12-29T08:40:00.008-08:00

San Diego Research Ethics ConsortiumSalk Institute for Biological Studies

Parthenogenetic stem cell lines: Ethical considerations

International Stem Cell’s Director of Research and Therapeutic Development, Nikolay Turovets, PhD, presents “How is Parthenogenesis Done?”

How is Parthenogenesis Done? (ANIMATED)

RegBlog: Over-Regulation of Parthenotes Stifles Valuable Scientific Research - by Sean J. Kealy

2011-12-16T08:38:00.000-08:00

A recent article in Scientific American questioned whether research on stem cell lines derived from unfertilized eggs was too tightly regulated by the federal government. Now that technology allows the creation of stem cells without fertilization, there is no question that federal laws and guidelines are overly restrictive, causing a detrimental effect on valuable scientific inquiry.

Since 1996, Congress has included the Dickey-Wicker Amendment in the annual federal budget. This amendment was a conservative reaction to what some considered to be scientific research that showed little respect toward life.

For example, speaking to the Senate in 1996, Robert Smith (R-NH) said, “Just because a private party wants to destroy life, why should Government force taxpayers to give their blessing to that act? Let private parties use private money for their ethically challenged experiments.” Similarly, Representative Jay Dickey (R-AR) said, also in 1996, that embroyonic research was “an attack on the sanctity of life,” and pointed out that several pro-life organizations supported the amendment.

Please click here to read the complete article.

Source: http://www.law.upenn.edu/blogs/regblog/2011/12/over-regulation-of-parthenotes-stifles-valuable-scientific-research.ht

Fox News: Stem Cell Cream Shows Benefits Similar to Collagen Injections

2011-12-15T12:32:00.000-08:00

Could a stem cell skin care line be coming to a store near you?

Researchers from the International Stem Cell Corporation said they have discovered a new class of pluripotent stem cells that have the same characteristics as embryonic stem cells – but don’t require destroying human embryos.

Dr. Simon Craw, vice president of the International Stem Cell Corporation, said extracts from these stem cells—called parthenogenetic stem cells—have shown benefits regarding skin care.

The scientists stumbled upon the discovery while doing stem cell research for the treatment of Parkinson’s disease. They essentially cracked open the cells and removed the proteins and peptides from the inside to use as part of a mixture for a topical skin cream.

Human Parthenogenetic Stem Cell Derived Neuronal Cells as a Tool for Parkinson’s Disease Treatment by Dr. Ruslan Semechkin

2011-12-14T09:05:00.000-08:00

Human Parthenogenetic Stem Cell Derived Neuronal Cells as a Tool for Parkinson’s Disease Treatment by Dr. R...

International Stem Cell Corporation to Present at the 4th Annual LD MICRO Growth Conference on December 8th

2011-12-01T08:23:00.002-08:00

International Stem Cell Corporation (OTCBB:ISCO) today announced that Co-Chairman Ken Aldrich and President and Chief Operating Officer Kurt May will be presenting at the 4th Annual LD MICRO Growth Conference in Los Angeles on Thursday, December 8, 2011 at 2:30 p.m. Pacific. The conference is being held at the Luxe Sunset Boulevard Hotel.

LD Micro founder Chris Lahiji stated, "We are excited to host over 100 companies for the first time in our history. What makes us especially proud, however, are all the interesting companies from our own backyard in Southern California, such as International Stem Cell, that are presenting this year."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
LHA
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation to Present Immune Matching Research Advances at Cell Science and Stem Cell Research 2011 Conference

2011-11-29T08:39:00.000-08:00

Executives from International Stem Cell Corporation (OTCBB:ISCO), a biotechnology company specializing in the research and development of stem cell-based therapies, will be presenting advances made in its research programs related to the use of immune-matched patient-specific parthenogenetic stem cells for neurological applications and genetic liver diseases at Cell Science 2011 in Philadelphia on November 29^th.

Vice President Ruslan Semechkin, Ph.D., will open the conference and discuss the latest trends in the use of stem cells to treat diseases of the central nervous system. A follow-on presentation will demonstrate that functional dopaminergic neurons can be successfully obtained from human parthenogenetic stem cells. Alina Ostrowska, Ph.D., the Company's Director of Translational Research, will present a new method of obtaining highly-enriched cultures of hepatocyte-like cells from pluripotent human stem cells.

Dr Semechkin comments, "I'm honored to be opening this conference and to be debating the latest advances in stem cell therapies. ISCO will also be presenting the most recent results from two of our most important research programs, where we continue to further characterize our parthenogenetic stem cell lines and their ability to form functioning liver-like cell and functioning neuron-like cells."

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human pluripotent stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals. ISCO maintains the world's largest collection of research-grade hpSC lines.

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

LifeLine Skin Care’s Holiday Gift Special PLUS an Autographed Copy of John Mauldin’s “Endgame”

2011-11-28T08:44:00.001-08:00

Happy Holidays from Lifeline Skin Care and John Mauldin!

Check Out LifeLine Skin Care’s Holiday Gift Special PLUS an Autographed Copy of John Mauldin’s “Endgame”

• Lifeline Defensive Day Moisture Serum (1 oz.)

• Lifeline Recovery Night Moisture Serum (1 oz.)

• In a beautiful Signature Gift Box

• An original, autographed copy of John Mauldin's newest book, Endgame

Specially priced at $310 ($368+ value!)

Plus Free Shipping to US addresses only*

The Lifeline gift box will ship on or before December 9; the autographed book will ship separately within six weeks of receipt of order.

Or call Customer Service: 1-877-764-9707

Monday-Friday | 9 am-5 pm PST

*International orders can be shipped via USPS Priority Mail for an additional $25. Depending on the destination, order date and Customs clearance, delivery can take from 5-30 days. Exact delivery date cannot be guaranteed.

Lifeline Skin Care | 5950 Priestly Dr. | Carlsbad, California 92008 | United States

Listen to International Stem Cell Corporation's November 17th Business Update Conference Call

2011-11-21T08:44:00.000-08:00

To listen to International Stem Cell Corporation's November 17th Business Update Conference Call, please click HERE

International Stem Cell Corporation's Kenneth Aldrich - The Wall Street Transcript

2011-11-17T09:55:00.002-08:00

If trouble viewing, please click here - International Stem Cell - TWST

International Stem Cell to Hold Business Update Conference Call on November 17th 10am PST/1pm EST

2011-11-16T10:25:00.000-08:00

International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Thursday, November 17, 2011 at 1:00 p.m. Eastern (10:00 a.m. Pacific). President and Chief Operating Officer Kurt May and Co-Chairman Ken Aldrich will provide an update on the business, including a discussion of recently announced third quarter results.

Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.intlstemcell.com.

A telephone replay will be available approximately one hour after the conclusion of the call by dialing (877) 660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 383602. The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

LHA

Don Markley

310-691-7100

dmarkley@lhai.com

Letter to the International Stem Cell Corporation Shareholders and Followers

2011-11-15T17:42:00.001-08:00

To the shareholders and followers of International Stem Cell Corporation:

You’ve likely seen stem cells in the news recently, and we’d like to take an opportunity to give you our views on two of the recent announcements.

First, International Stem Cell Corporation announced yesterday earnings for the third quarter 2011. We’ll be hosting a conference call on Thursday, November 17, 2011 at 10:00 AM PST to discuss key developments in the quarter, provide our outlook and answer your questions. Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company’s Web site at www.internationalstemcell.com.

Second, Geron’s decision, announced yesterday, to terminate its stem cell R&D program in no way affects ISCO’s current strategy or developmental activities, nor does it alter our optimism for the potential of stem cells to eventually treat a broad-range of diseases and conditions. While Geron may be reprioritizing programs, we are committed to the course we are on.

Additionally, ISCO will continue its discussions with CIRM regarding possible funding for our truly unique parthenogenesis technology, particularly in light of the $25 million previously earmarked for Geron coming available for other investments.

Thank you for your interest in ISCO. We hope you will join us for the conference call.

Sincerely,

Ken Aldrich

International Stem Cell Corporation Announces Third Quarter 2011 Financial Results

2011-11-15T08:55:00.001-08:00

CARLSBAD, California – November 15, 2011 - International Stem Cell Corporation (ISCO) (OTCBB:ISCO) today announced financial results for the three-month and nine-month periods ended September 30, 2011. ISCO is a development-stage biotechnology company that created, patented and is commercializing a powerful new stem cell technology called parthenogenesis which promises to advance significantly the field of regenerative medicine.

ISCO reported revenue of $0.84 million for the quarter ended September 30, 2011, a 141% increase from the same period of the prior year. For the nine months ended September 30, 2011, the Company reported revenue of $3.47 million, a year-over-year increase of 227%. The increases in revenue was driven by strong sales from the initial launch of ISCO’s wholly-owned subsidiary Lifeline Skin Care (LSC), which commenced operations in the fourth quarter of 2010. In addition, steady growth in sales from ISCO’s other wholly-owned subsidiary, Lifeline Cell Technology (LCT), contributed to the increases in revenues for both periods.

The Company continued to invest in the development of new technologies, products and channels of distribution. For the three months ended September 30, 2011, development expenses, excluding cost of sales, were $3.60 million, an increase of 15% compared to the third quarter of 2010, reflecting increased R&D activities on therapeutic programs and new product development for both subsidiaries. Sales and marketing expenses related to our skin care products, partially offset by a reduction in general and administration expenses, also contributed to the increase in development expenses.

For the nine months ended September 30, 2011, development expenses, excluding cost of sales, were $10.77 million, an increase of 30% when compared with the prior year period. The increase is attributed primarily to increased research activities on therapeutic products and product development programs for LSC and LCT, increased stock-based compensation expense, increased headcount and higher general corporate expenses coupled with increased sales and marketing expenses related to our skin care products.

Dr. Andrey Semechkin, co-Chairman and CEO, commented “We are pleased with the rapid growth in sales of our two subsidiaries, LSC and LCT. Together, these business units are providing much-needed capital to help support our growth as well as the research leading to the development of new stem cell technologies and products.” Kurt May, President and COO, noted “Our focus continues to be on maximizing the performance of our operating subsidiaries, advancing the development and commercialization of our therapeutic products and strengthening our organization and operating systems to accommodate our anticipated rapid and significant growth.”

Third Quarter 2011 Highlights:

Important developments and milestones for International Stem Cell in the third quarter included:

-- Continuing to solidify its leadership team with the addition of Linh Nguyen as ISCO’s new Chief Financial Officer. Further, the Board of Directors elevated Kurt May to President and Chief Operating Officer and Dr. Semechkin to co-Chairman of the Board and Chief Executive Officer.

-- Renewing the marketing agreement with John Mauldin to promote its Lifeline Skin Care products and commenced a new sales channel to resorts and destination spas.

-- Lifeline Cell Technology began selling products through new distribution channels in Japan, Korea, Singapore, Malaysia and Indonesia, expanding its business throughout Asia.

-- ISCO scientists successfully completed the first series of preclinical studies designed to support the application of neuronal cells derived from hpSCs. These experiments were designed to demonstrate that the derived neuronal cells were able to survive in mouse brains without giving rise to tumors.

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

Andrey Semechkin, CEO & Co-Chairman

760-940-6383

aes@intlstemcell.com

International Stem Cell Corporation

Kurt May, President & COO

760-710-3294

kmay@intlstemcell.com

International Stem Cell Corporation

Linh Nguyen, CFO

760-940-6383

LNguyen@intlstemcell.com

Lippert/Heilshorn & Associates

Don Markley

310-691-7100

dmarkley@lhai.com

Please click on the pages below to enlarge.

1) The Company restated its financial statements for the year ended December 31, 2010 and the quarter ended March 31, 2011. See explanatory note after cover page of this 10-Q and Note 1 to the unaudited condensed consolidated financial statements. See accompanying notes to the unaudited condensed consolidated financial statements

The Wall Street Transcript Exclusive Interview With The Co-Chairman And Co-Founder: International Stem Cell Corporation (ISCO) - Kenneth C. Aldrich

2011-11-14T15:20:00.001-08:00

November 14, 2011 - The Wall Street Transcript has just published Biotechnology and Pharmaceuticals Report offering a timely review of the sector. This Special Report contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. Please find an excerpt below.

View This Special Report

Recent Wall Street Transcript Special Reports.

Kenneth C. Aldrich is Co-Chairman and Co-Founder of International Stem Cell Corporation, a publicly traded regenerative-medicine company. International Stem Cell has created a new class of human stem cells that can do all the things embryonic stem cells can do, but without the ethical issues that arise from the use of human embryos and with the potential to solve the problem of immune rejection in stem cell therapy. Mr. Aldrich holds degrees, with honors, from both Harvard University and Harvard Law School and practiced law with the Los Angeles-based firm of O'Melveny & Myers before leaving in 1969 to build a career in finance.

TWST: Let's start with a short history and overview of International Stem Cell Corporation's operations.

Mr. Aldrich: International Stem Cell (ISCO) began back in 2007 as a public company built around our development of a new class of stem cells that had all of the positive characteristics of embryonic stem cells in that they could become any cell in the body but avoided the ethical issues because we didn't use a fertilized egg. These cells are called parthenogenetic stem cells. We built the company around that core technology, in-licensed over a 100 different patents and patent applications from other companies, primarily from Advanced Cell Technology, as well as having our own recent patents covering the process for developing parthenogenetic stem cells. So we are in a group of companies that use a true pluripotent stem cell, which is a cell that can become any cell in the body.We are different from embryonic stem cells in that we do not involve a fertilized egg, and there is no destruction of human life or anything that could become human life.

TWST: Your first series of preclinical studies designed to support the safety and utility of neurones was successful. Would you comment on the opportunity addressed by this study and its success?

Mr. Aldrich: Yes, we actually are involved in three studies of animals. These are not FDA preclinical. They're our own laboratory animal studies conducted through third-party universities. We've done work with retinal cells demonstrating that they do indeed engraft and do not produce teratomas, which can become a cancer. We've also produced liver cells and performed similar studies with those, and with positive results.

Most recently, we've done the same thing with neuronal cells that we've developed. So we've developed three classes of cells that are now being tested in animals, and we'll repeat those tests until we're very confident that we have the kind of data that we are ready to go into the FDA with. All the indications are very, very good so far.In addition, we've grown a human cornea in a petri dish, and we're working now outside the U.S., primarily in India, to develop those corneas as a cornea transplant, a substitute for using cadaver corneas.

TWST: Are there other companies working along the same lines as International Stem Cell? What are your competitive advantages?

The remainder of this 27 page Biotechnology and Pharmaceuticals Report can be immediately viewed by purchasing online.

California Stem Cell Report Article: “Trounson, Parthenotes and International Stem Cell”

2011-11-11T15:09:00.000-08:00

Source: http://californiastemcellreport.blogspot.com/2011/11/trounson-parthenotes-and-international.html

The president of the California Stem Cell Agency, Alan Trounson, popped up in a recent article in Scientific American dealing with a method for creating pluripotent stem cells from unfertilized human eggs.

The piece by Julia Galef said that "many investigators remain frustrated" that the method "remains offlimits" for federal funding, a barrier that does not apply to financing from the $3 billion California stem cell agency.

Galef wrote that one California firm, International Stem Cell Corp., of Carlsbad, is using the method to develop products. She said the firm's work involves "a process called parthenogenesis, in which researchers use chemicals to induce the egg to begin developing as if it had been fertilized. The egg—called a parthenote—behaves just like an embryo in the early stages of division. Because it contains no genetic material from a father, however, it cannot develop into a viable fetus."

To read the complete article on "California Stem Cell Report", please click here

International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care

2011-11-10T08:16:00.002-08:00

International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline's products in Australia and New Zealand under Lifeline's own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company's website www.lifelineskincare.com.

The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.

"I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report," said Dr. Keller. "Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they've seen are amazing."

Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.

"In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand."

Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin's own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
International Stem Cell Corporation
Donna Queen, Vice President of Marketing and Business Development
760-710-3295
dqueen@lifelineskincare.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation Comments on WSJ Article “Hope for Stem-Cell Treatment of Parkinson's”

2011-11-09T11:48:00.002-08:00

Article: Hope for Stem-CellTreatment of Parkinson's BY GAUTAM NAIK – The Wall Street Journal HEALTH

“Researchers have used stem cells obtained from human embryos to successfully treat Parkinson's disease in mice and rats, a key step in the quest to develop a similar approach for people.

In a study published Sunday in the journal Nature, scientists described how they converted human embryonic stem cells into nerve cells that produced the brain chemical dopamine. When these nerve cells were transplanted into the brains of mice and rats, they released dopamine and got rid of the animals' Parkinson's symptoms. The cells were also successfully transplanted into rhesus monkeys, whose biology is closer to that of humans.”

SOURCE - To read the complete article on The Wall Street Journal HEALTH site, please click HERE

Comments from International Stem Cell Corporation:

International Stem Cell Corporation (ISCO) announced in July 2011 the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells. The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSCs), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

Dr. Andrey Semechkin, Co-Chairman and CEO of ISCO, comments: “The ability of neuronal cells to become a specific type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”

Forward-looking Statements

Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Video: StemCellTV interviews Donna Queen of Lifeline Skin Care at the California Academy of Cosmetic Surgery Annual Conference

2011-11-08T10:55:00.002-08:00

StemCellTV interviews Donna Queen of Lifeline Skin Care at the California Academy of Cosmetic Surgery Annual Conference in San Diego October 2011.

Seeking Alpha Article: 3 Contenders To Be The First Profitable Stem Cell Company by Ryan Pollock

2011-11-02T10:17:00.000-07:00

Seeking Alpha is a "stock market news and financial analysis website, including free earnings call transcripts, investment ideas and ETF & stock research written by finance experts". Ryan Pollock recently initiated coverage on International Stem Cell Corporation (ISCO). Although the views and opinions are Mr. Pollock’s own and not necessarily those of ISCO, we thought you would be interested in his insights about our company.

To read the complete article 3 Contenders To Be The First Profitable Stem Cell Company, please click HERE

International Stem Cell Comments on Recent SCIENTIFIC AMERICAN Article: “You Say Embryo, I Say Parthenote”

2011-10-21T08:32:00.002-07:00

“We at International Stem Cell Corporation (ISCO.OB) are finding it increasingly gratifying that mainstream and highly respected publications like Scientific American are now beginning to take notice of the fact that our Parthenogenetic Stem cells have tremendous potential to accelerate disease cures, lower health care costs, and create jobs here in America -- all free from the bioethical issues that have long clouded the stem cell debate."

Like embryonic stem cells, our Parthenogenetic stem cells can be converted into almost any kind of cell that might ever be needed for therapy, but can also provide a solution to the two biggest issues that have surrounded embryonic stem cell research: 1) the ethics of destroying a fertilized embryo, which our process never does, and 2) the problem of immune rejection by the patient. We hope you enjoy the attached article."

Ken Aldrich, Founder and Co-Chairman, International Stem Cell Corporation

October 21^st, 2011

“You Say Embryo, I Say Parthenote”

Stem cells from unfertilized eggs may be too tightly regulated

By Julia Galef

Article: http://www.scientificamerican.com/article.cfm?id=you-say-embryo-i-say-parthenote

Source: Scientific America November 2011

The Ellis Martin Report: Interview with International Stem Cell Corporation's Founder and Co-Chairman Kenneth Aldrich

2011-10-17T12:55:00.000-07:00

Brief Overview:
Lifeline Skin Care – LLSC

Remodeled marketing and structure of subsidiary to reach broader base of users and use multiple distribution channels including International distribution network, spas and resorts plus increased product supply.

Lifeline Cell tech - LLCT

Recently seeing results from distributorships expansion throughout several countries in Asia.

International Stem Cell Corporation - ISCO

Started first animal trials with a class of neurons developed with our parthenogenic stem cells, proprietary only to ISCO, to develop what we think has great promise for treating Parkinson’s disease and possibly other diseases.

Patrick Cox's Breakthrough Technology Alert: International Stem Cell Corp. Progressing Despite Incompetent MSM

2011-10-12T09:25:00.001-07:00

agorafinancial.com | contact us | login

October 11, 2011

International Stem Cell Corp. Progressing Despite Incompetent MSM

Dear Breakthrough Technology Alert Reader,

"American journalism (like the journalism of any other country) is predominantly paltry and worthless. Its pretensions are enormous, but its achievements are insignificant."

-- H.L. Mencken

Last week, an article by Rob Stein appeared in The Washington Post titled "Scientists Report Possibly Crucial Advance in Human Embryonic Stem Cell Research." Stein, whose credentials include science editor positions at NPR and The Washington Post, describes the use of cloning techniques to turn oocytes, immature eggs, into embryonic cells. The first one-sentence paragraph is as follows:

"Scientists reported Wednesday that for the first time, they had used cloning techniques to generate embryonic stem cells containing the genes of specific patients."

Frankly, I don't know what that sentence means. Somatic cloning of stem cells has been going on for years at places such as the Harvard Stem Cell Institute and the University of California San Francisco. It's not a particularly difficult thing to transfer adult DNA into an embryonic stem cell. Maybe the researchers said that it was the first time that "they" had used cloning techniques to make ESCs and the writer misinterpreted their statements. I have no idea.

Moreover, that sentence includes the word "patients." There were no patients involved in the study. It was a laboratory demonstration of a cloning technique in which DNA from mature cells is transferred into immature eggs, oocytes. Then, the oocytes transformed into stem cells with the implanted genes. The interesting thing about the procedure, which you can access here, is that the DNA from a normal cell, from two parents, was added to a cell with only a mother's genes.

This resulted in a cell with the DNA of three people -- a triploid cell. While fascinating, it also raises all kinds of scientific and safety issues. We have no idea what triploid cells would actually do if they were implanted in a patient. With extra haploid matching points, they might even be immunocompatible with no one.

I do, however, have a great script idea if somebody with money would like to hear the pitch. I'm thinking Species meets Mommie Dearest. Regardless, the possibility that triploid cells will be therapeutically useful in the foreseeable future is very low.

This brings me to the real flaw in the story. Read the second sentence/paragraph:

"The step marks a possibly pivotal advance toward the long-sought goal of creating stem cells that could be used to treat many major diseases, because they would not be rejected by patients' immune systems."

Balderdash. There are at least two solutions already available for dealing with immune rejection -- induced pluripotent stem cells (iPSCs) and human parthenogenic stem cells (hpSCs).

The iPS cell technology uses an individual's own cells to create cells that are functionally equivalent to embryonic stem cells. These would be compatible with the donor. The other solution is the human parthenogenic stem cells developed by International Stem Cell Corp. (OTCBB:ISCO). These, scientists believe, will solve the immune rejection problem on a mass-market basis.

ISCO long ago demonstrated that they have made the "pivotal advance" using oocytes, to which the Post article refers. ISCO scientists discovered and patented the techniques that successfully create human parthenogenic stem cells (hpSCs), which can be programmed to become any other cell type. With ISCO's cell banks, which will match the various HLA profiles of the human species, the immune rejection problem will be solved for the vast majority of the human race.

You will recall from my recent issue about ISCO that the company has already begun collecting oocytes to create these parthenogenic cells lines. It does so with complete approval of regulatory and ethical agencies.

As you know, it took ISCO many years and millions of dollars to accomplish their technological breakthrough. Interestingly, it had previously been done, apparently in an accidental and nonreproducible manner. Stem cell scientist Woo Suk Hwang of Seoul University announced in 2004 that he had produced a stem cell line derived from an embryonic human clone. Later, it was discovered that Hwang did not have a cloned stem cell line. He had a parthenogenic stem cell line.

Though Hwang was disgraced, the irony is that cloned stem cell lines are far easier to produce than hpSC lines. I don't understand all the details about what he did, wrong or right. The irony is this, however: If he had presented his stem cells as hpSCs, he might have been acclaimed a scientific hero, instead of the super-villain he is considered today.

The Washington Post article goes on to cite the usual stem cell controversies. Those opposed to ESC research have voiced opposition to the triploid stem cell technology when asked. They believe the triploid cells are embryonic stem cells. Since they are, in a sense, fertilized, that may be true. It's not at all clear, though, that they could develop into an embryo. I doubt it.

Also, the fact that some fertility therapy patients were paid well for oocytes unneeded in the fertilization process has caused serious concern among feminist commentators. They are seriously concerned. Seriously.

The big point, however, is that this article badly misrepresents the state of the science. ISCO scientists have long had the ability to create pluripotent stem cells using oocytes. More to the point, cells made using their process have none of the ethical issues of these triploid cells. They are not fertilized and cannot become embryos. They require no genetic manipulation. No foreign DNA is inserted into them. The company does not pay for oocytes and has followed every ethical guideline acquiring them.

The Wall Street Journal apparently picked up on the "breakthrough" story and helped spread the disinformation, as did other news outlets and bloggers. I'm not, per se, a journalist, but if I were writing for a nationally read publication that purports to present science accurately, I would have started by checking around to see if there were other perspectives on stem cells from parthenogenic oocytes.

In fact, I did a simple Google search using key words "parthenogenic" (or "parthenogenetic"), "stem" and "cell." The first page yielded this link to ISCO's description of their human technology.

Then, looking around the site, we find a list of respected scientific partners who are assisting in further research on ISCO's hpSCs, as well as some of their research areas.

They include:

Novocell Inc., San Diego, Calif., endocrine pancreas cells.

University of California, San Francisco, Calif., hepatocyte cells.

University of California, Irvine, Calif., retinal pigment epithelium.

University of Wurzburg, Germany, neuronal cells.

The Scripps Research Institute, La Jolla, Calif., characterization of human parthenogenetic stem cells.

None of these organizations is inaccessible. You can find their phone numbers on the innerwebz, and it has been my experience that scientists are more than happy to tell journalists what's really going on. Oh, well.

Having spent so much time in debunking mode, now I feel like I ought to at least bring you up-to-date on some new developments at ISCO. Several important events have, in fact, occurred lately.

ISCO to Expand Cosmeceutical Product Lines

One, ISCO has been perfecting the process of growing and preserving the active ingredient in parthenogenic stem cells used for their cosmeceutical skin care product line. As a result, they've been able to stockpile enough of the growth factors found in stem cells to allow additional marketing efforts. In the past, availability of product has limited those efforts.

Moreover, the company has announced development of several new skin care products, including one designed to work on the sunken area under the eyes. The skin care line, while not cosmically meaningful, is doing very well for the company and is on track to fund serious work, such as ISCO's liver cell science.

Also, ISCO has brought in an experienced corporate executive to help move the company forward. Dr. Andrey Semechkin, currently CEO, will become co-chairman. Kurt May, currently senior vice president, will take the helm as president and COO.

From the press release:

"Prior to joining ISCO, Mr. May was a senior executive with GTE Corp. and with PriceSmart Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and assistant dean of UCSD's Rady School of Management from 2005-09.

"During his tenure as PriceSmart's chief operating officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability and expanding staff from 356 to more than 4,200.

"'In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success,' said Kenneth Aldrich, co-founder and co-chairman of ISCO."

Yours for transformational profits,

Patrick Cox

Please note: We sent this e-mail to: PATRICK COX because you subscribed to this service.

To log in to the website, please visit http://breakthroughtechnologyalert.agorafinancial.com/ and login using your permanent username and passwords below:

Please note that if you have multiple e-mail addresses associated with this account, the username and password above may be blank. To cancel by mail or for any other subscription issues, write us at:

Order Processing Center | Attn: Customer Service | P.O. Box 960 | Frederick, MD 21705 USA

Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice.

We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

©2011 Agora Financial, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web) , in whole or in part, is strictly prohibited without the express written permission of Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202.

Wurzburg, Germany, neuronal cells.

The Scripps Research Institute, La Jolla, Calif., characterization of human parthenogenetic stem cells.

Having spent so much time in debunking mode, now I feel like I ought to at least bring you up-to-date on some new developments at ISCO. Several important events have, in fact, occurred lately.

ISCO to Expand Cosmeceutical Product Lines

From the press release:

Yours for transformational profits,

Patrick Cox

Please note: We sent this e-mail to: PATRICK COX because you subscribed to this service.

To log in to the website, please visit http://breakthroughtechnologyalert.agorafinancial.com/ and login using your permanent username and passwords below:

customer number: 45650415

username:COX48935

password:21202

Please note that if you have multiple e-mail addresses associated with this account, the username and password above may be blank. To cancel by mail or for any other subscription issues, write us at:

Order Processing Center | Attn: Customer Service | P.O. Box 960 | Frederick, MD 21705 USA

International Stem Cell's Research Scientists Successfully Completed the First Series of Preclinical Animal Trials of Neuronal Cells

2011-10-11T12:34:00.000-07:00

International Stem Cell Corporation (OTCBB: ISCO) announces today successful completion of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). These initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson's disease.

Dr. Albrecht Müller, Professor at the Institute of Medical Radiology and Cell Research, Würzburg University (Germany), commented: "Human parthenogenetic stem cells are potentially very promising candidates for use in regenerative medicine primarily because of the possibility that they immune-match a large number of recipients. The result of these safety and survival studies is a very important step along the path towards the clinical use of such cells."

Although most cases of Parkinson's disease occur in people with no family history of the disease, a number of genetic mutations have nevertheless been identified with the disease. While the inheritance pattern is largely unknown, as a condition with a genetic component "autologous" treatment, that is to say treatment using the patient's own cells, is far from ideal and does not offer the potential of a cure. To treat Parkinson's disease successfully a source of cells free of the mutated genes is necessary. Human parthenogenetic stem cells provide this source, as well as superior immune-matching capabilities.

ISCO currently has the world's largest collection of human parthenogenetic stem cells including heterozygous examples, where the cells immune match the donor as is the case with induced pluripotent stem cells (iPS), and homozygous examples which immune-match millions of individuals. ISCO is actively expanding this collection of cell lines and creating a "bank" of homozygous human parthenogenetic stem cells that can be used as a platform to not only reduce the chances of tissue rejection, but also make cellular-based therapies economically more viable.

Dr. Ruslan Semechkin, ISCO's Vice President, commented: "One of ISCO's main therapeutic targets is treatment of Parkinson's disease, a common neurodegenerative disease in the US, where the current standard of care is designed mostly to treat the symptoms, but not the disease. These results clearly represent an important step towards the therapeutic application of human parthenogenetic stem cells derived cells in addressing the basic underlying mechanisms and potentially transforming the treatment of neurodegenerative diseases."

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C. Aldrich, co -Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation's Ken Aldrich Comments on Recent News about SCNT - Somatic Cell Nuclear Transfer

2011-10-11T06:24:00.001-07:00

Last week's newspapers carried the news of what was widely described as a significant “breakthrough” in stem cell science: the first successful human use of a technology known as Somatic Cell Nuclear Transfer (also referred to as SCNT). This is essentially a variation on a process that was used some years ago to create a cloned sheep named Dolly. Cloning has since been used commercially in various animal applications.

What is strange about the flurry of publicity about this discovery, however, is the almost total lack of commentary about a method of creating stem cells that has been available to researchers for almost half a decade, holds the same kind of promise as embryonic stem cells for providing cells for the treatment of almost any kind of degenerative disease, is free of ethical issues (including issues with egg donation), and can potentially make immune matched cells available to any patient anywhere in the world, on demand, at a far lower cost.

I am talking about human stem cells derived from a process called, “Parthenogenesis”, developed and first announced in 2007 by a company called International Stem Cell Corporation, whose discoveries were first published in the peer reviewed journal, Cloning and Stem Cells, edited by the scientist who first created “Dolly”, the first cloned animal.

I realize that I could be accused of bias because I am one of the founders of International Stem Cell, but, in fact, our company also owns license rights to some of the key intellectual property that is required to create cells through SCNT technology and our scientists are very familiar with its promise and its limitations. As a result, International Stem Cell will benefit from the development of either technology, but it is important that the public and the scientific community be fully aware of all alternatives in the field of regenerative medicine, not just the ones that capture public imagination at any particular time.

For that reason, I would like to comment on Parthenogenesis and compare it to SCNT technology and the other options available today. The technology known as "Parthenogenesis" begins with human eggs that are created and used every day throughout the world for in-vitro fertilization (IVF). What is not generally known is that the IVF process can often result in the creation of far more unfertilized eggs than will ever be needed for fertility purposes. It is possible, with informed consent from the IVF patient, to hold back some unfertilized eggs for creation of parthenogenetic stem cells, all at no additional risk to the donor.

Instead of wasting those eggs, what International Stem Cell does, with the full consent of the donors, is to save those eggs from the trash bin, induce them through a simple, but patented, process to create the small cluster of cells from which a stem cell line can be created that can be used for scientific research and the eventual treatment of patients with such diseases as Parkinson’s, Macular Degeneration, Liver Disease, Diabetes, and possibly many others.

What are critical to understand in thinking about Parthenogenetic stem cells are six things:

Like embryonic stem cells and SCNT cells, these cells can be converted into almost any cell in the human body and thus have enormous potential for human therapy.

Unlike embryonic stem cells, the human eggs used to create parthenogenetic stem cells are never fertilized and cannot become a human being. No viable embryo is ever harmed or destroyed.

Unlike SCNT cells, parthenogenetic stem cells require no genetic manipulation or insertion of foreign DNA.

No donor is every subjected to any additional physical risk beyond what she has already agreed to as part of the IVF procedure in which she elected to participate. In fact, all egg donors voluntarily participate through a very transparent, peer-reviewed, and medically supervised process. Protocols are approved by Independent Review Boards (IRBs) to protect the safety of donors and by an independent Stem Cell Research Oversight (SCRO) committee to insure compliance with state laws and research ethics, regulations established by the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services (HHS) Office for Human Research Protections, in addition to state-level requirements.

The cell lines that are produced from this method, unlike cell lines from embryonic stem cells or from SCNT, can potentially be matched to millions of people in the same way that an organ transplant is matched between donor and patient. In fact, by some estimates, as few as 100 parthenogenetic stem cell lines could provide immune-matched cells to over 50 percent of the world’s population, and could accelerate disease therapies and treatments for severe chronic conditions, including diabetes, spinal cord injuries, liver diseases, blinding diseases such as macular degeneration, and neural diseases such as Parkinson’s and Alzheimer’s.

The possibility of immune-matching to millions of persons can vastly reduce the potential costs relative to SCNT or embryonic stem cell technology, which create stem cell lines that can match only a few persons.

In summary, what we find particularly exciting about Parthenogenesis is that it addresses all the major issues of stem cell therapy. It is free from the traditional bioethical issues that have clouded federal policies towards stem cell research because parthenotes are derived from unfertilized eggs and cannot develop into human beings. Parthenogenesis is not cloning, and it does not involve the creation or destruction of a viable human life. Also, the creation of a parthenogenetic stem cell bank will not require a large number of human eggs and many individual donors, as has been a fear surrounding other stem cell approaches. Parthenogenesis is at once effective and efficient, and one line of parthenogenetic stem cells can be used to create treatments for millions of persons. This is not a situation where one line must be made for each patient treated.

To learn more about Parthenogenesis, visit www.internationalstemcell.com, or click on ISCO.OB at any financial web site for information about our company.

International Stem Cell Corp. Chairman Kenneth Aldrich Comments on Recent TIME Article “A Stem Cell First: Using the 'Dolly' Method on Human Cells”

2011-10-06T16:03:00.000-07:00

“Since we at International Stem Cell Corporation (trading symbol: ISCO.OB) are licensees of some of the key intellectual property necessary to use SCNT in therapeutic products, we were delighted to read about this new discovery. However, what disappointed us somewhat was the failure of most news reports to mention that a technology already exists that solves the same ethical problems and has the potential also to solve many of the problems of immune rejection that worry scientists who are working with cells obtained from fertilized embryos.

That technology is called "Parthenogenesis" and results in a "cell line" that can provide an essentially unlimited supply of human cells for a wide range of therapeutic purposes, yet does not involve the destruction of any fertilized embryo and results in cells that can be matched to large groups of people who may not even know the patient, much like the way blood from donors can be stored and used by accident victims as needed. Unlike the SCNT cells, parthenogenetic cells require no genetic manipulation or insertion of foreign DNA.

Our scientists at ISCO created and patented the process for making such human parthenogenetic stem cell lines and have already successfully made liver cells, cornea cells, retina cells and nerve cells from those cell lines. Each of these applications is being studied as a possible future source of transplanted cells to treat diseases such as Parkinson's, Liver Disease, Macular Degeneration, and others.

To learn more about parthenogenesis, visit our website at www.internationalstemcell.com or click on ISCO.OB at any financial web site for information about our company.”

Kenneth C. Aldrich

Chairman

International Stem Cell Corporation

TIME Article – A Stem Cell First: Using the 'Dolly' Method on Human Cells

http://healthland.time.com/2011/10/05/a-stem-cell-first-using-the-dolly-method-on-human-cells/

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Forward-looking Statements

Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Names Dr. Andrey Semechkin as Co-Chairman and Kurt May as President and Chief Operating Officer

2011-10-06T11:04:00.001-07:00

International Stem Cell Corporation (OTCBB:ISCO) today announced that its Board of Directors designated Dr. Andrey Semechkin, the Company's Chief Executive Officer, as a Co-Chairman with the Company's founder, Kenneth Aldrich, and also named Kurt May as President and Chief Operating Officer, effective immediately. Mr. May is currently Senior Vice President and this represents both a promotion and the delegation of additional duties and responsibilities consistent with his increasingly important role in the future of ISCO.

Dr. Semechkin commented, "Kurt May is an extremely capable executive who has managed both a multi-billion dollar public company and a successful life sciences startup company. His willingness to assume operational responsibilities for ISCO will allow me, as CEO, to focus more intently on scientific and strategic initiatives that are central to developing ISCO into a major force in the world of stem cell therapy. Working together with the fine team of executives and scientists already within ISCO, I have high hopes and confidence we can reach that goal."

Prior to joining ISCO, Mr. May was a senior executive with GTE Corporation and with PriceSmart, Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and Assistant Dean of UCSD's Rady School of Management from 2005 to 2009.

During his tenure as PriceSmart's Chief Operating Officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability, and expanding staff from 356 to more than 4,200.

"In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success," said Kenneth Aldrich, Co-Founder and Co-Chairman of ISCO.

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

International Stem Cell Corporation

Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Representative Brian Bilbray Meets with International Stem Cell Executives to Discuss Research Funding

2011-09-29T08:44:00.001-07:00

International Stem Cell Corporation (OTCBB: ISCO) today announced that Representative Brian Bilbray recently met with Company executives, including Chairman Kenneth Aldrich, President and Chief Executive Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss key federal government issues relating to stem cell research. Rep. Bilbray represents California's 50th congressional district, which includes portions of San Diego's North County.

Following the meeting, Rep. Bilbray stated, "I have tremendous respect for the innovative healthcare companies in my district, such as International Stem Cell, that are at the forefront of developing important new treatments and therapies. I'm committed to helping remove unnecessary regulations and barriers that may inhibit the research of new life science technologies, and I greatly appreciate the efforts of ISCO's management team to clarify many of the issues surrounding their work."

Said Dr. Semechkin, "We are very pleased to have the opportunity to meet with Congressman Bilbray and explain the importance of our parthenogenesis technology and how it differs from human embryonic stem cell development, particularly from an ethical standpoint. We look forward to continued discussions with Congressman Bilbray and his colleagues regarding the Dickey-Wicker Amendment. We believe that with increased understanding of our technology the National Institutes of Health (NIH) will support parthenogenesis research and development."

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

Lippert/Heilshorn & Associates

Don Markley

310-691-7100

dmarkley@lhai.com

Lifeline Skin Care Video: Care For Your Skin with Lifeline Skin Care

2011-09-19T16:17:00.000-07:00

Stem Cell Skin Care

Born Different.

Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”. ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells.

International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes.

Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.

International Stem Cell Corporate (ISCO.OB) Produced by Big Sky Productions - 9 Minute Version

2011-09-12T13:18:00.001-07:00

Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.

This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).

Executive Producer, Ellis Martin.

Producer and Creative Director, Narrator, Editor: Bob Lange

http://www.ellismartinreport.com http://www.intlstemcell.com

contact: bigskymedia@yahoo.com

ChartPoppers.com Interviews Kenneth Aldrich, CEO of International Stem Cell Corp. (OTCBB:ISCO)

2011-09-08T15:00:00.000-07:00

Chartpoppers.com - The #1 rated Penny Stocks Newsletter for Penny Stock Tips, Stock Market information, Penny Stock Picks, Trading Articles, and Day Trading.

ChartPoppers.com is pleased to announce the availability of an exclusive audio interview with Kenneth Aldrich of International Stem Cell Corporation

Please click here to listen to the complete interview.

Ellis Martin Report with International Stem Cell Corporation's Senior VP Kurt May

2011-09-08T11:13:00.001-07:00

In this interview Ellis Martin speaks with Kurt May, Senior Vice-President of International Stem Cell Corporation (ISCO.OB). Mr. May discusses his role with the company and their unique development of the parthenogenic stem cell derived from unfertilized embryonic eggs. He oversees the growth of the company's LIfeline Stem Cell and Lifeline Skin Care revenue generating divisions. The question of immune rejection is overcome with their proprietary technology.

Listen to learn more. http:://www.intlstemcell.com http::/www.ellismartinrepot.com
Contact: martinreports@gmail.com

International Stem Cell Corp is a paid sponsor of The Ellis Martin Report

International Stem Cell to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12

2011-09-07T08:37:00.000-07:00

International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 11:40 a.m. Eastern (8:40 a.m. Pacific). The conference takes place at the Waldorf Astoria Hotel in New York City.

A webcast of the International Stem Cell Corporation presentation can be viewed live at http://www.wsw.com/webcast/rrshq20/isco. The presentation will be archived and available at the same link for 90 days. After the conference, a link to the presentation will also be posted to the ISCO website, www.intlstemcell.com.

About International Stem Cell Corporation

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation

Kenneth C Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

Lippert/Heilshorn & Associates

Don Markley

310-691-7100

dmarkley@lhai.com

Video: The Promising Cells Presented by International Stem Cell Corporation

2011-09-06T09:01:00.001-07:00

This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).

Executive Producer: Ellis Martin

Producer and Creative Director, Narrator, Editor: Bob Lange

http://www.ellismartinreport.com http://www.intlstemcell.com

contact: bigskymedia@yahoo.com

Video Link - http://www.youtube.com/watch?v=CcXPMHqENys

Part 5: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

2011-08-29T08:58:00.003-07:00

In this interview, Ellis Martin speaks with Kenneth Aldrich of International Stem Cell Corporation (ISCO.OB) about continuing research and revenue generated by Lifeline Stem Cell technology, including Lifeline Skin Care Creams. Is International Stem Cell working on a cure for melanoma or cancer? Not directly, but the company believes that their technology is being used by their client companies doing research for these cures. Listen to the interview for full details. http://www.ellimartinreport.com http://www.intlstemcell.com contact:martinreports@gmail.com

International Stem Cell Corp is paid sponsor of The Ellis Martin Report. Forward looking statements may have been made in this interview.

International Stem Cell Corporation presents "The Promising Cells" Video

2011-08-25T09:38:00.004-07:00

In this video presentation, see and hear an overview of International Stem Cell Corporation (ISCO.OB). ISCO has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy. You'll hear directly from Executive Chairman, Kenneth Aldrich. Lifeline Cell Technology and Skin Care Products, revenue generating units of ISCO are also reviewed.

This presentation was produced by Big Sky Productions, INC (BGSI.OB), Co-Executive Producers Ellis Martin and Bob Lange.

contact: bigskymedia@yahoo.com

Onemedplace.com Interview - "International Stem Cell Corp Develops Similar Embryonic Stem Cells Without Fertilized Embryos"

2011-08-24T08:12:00.000-07:00

Ken Aldrich, Executive Chairman of International Stem Cell Corporation [OTC:ISCO] was interviewed by OneMedRadio where he discussed the company’s regenerative medicine therapies.

Brett Johnson: Good day, this is Brett Johnson in New York City with OneMedRadio. Today, I am with Ken Aldrich. He is the co-founder and executive chairman for International Stem Cell, symbol ISCO on the bulletin board. It is a Carlsbad, California company in the stem cell business. Ken, thanks for joining us today.

Kenneth Aldrich: Thank you. I appreciate the opportunity to speak with you.

BJ: Ken, go ahead and tell us a little bit about the business of International Stem Cell and what you guys are doing that’s unique and distinctive.

KA: I’d be happy to. International Stem Cell is in the regenerative medicine business broadly speaking. We produce and develop therapies that are based on what are called pluripotent stem cells. Pluripotent stem cell simply means a stem cell that can be converted (the technical word is differentiated) into any cell in the body and theoretically treat any kind of disease that can be treated with cell therapy.

There are today basically only two ways to create a pluripotent stem cell. One is what’s been around for ten years called embryonic stem cells derived from a fertilized human embryo, and the other is parthenogenesis, which is our own creation, our own patent. Our people really developed it from the very beginning.

They function very much the same but we have two unique advantages. One, we take the ethical issue right off the table. We do not use a fertilized egg and we never damage or destroy anything that could become a human being. And second, the DNA that results when we go through that process of using only an unfertilized egg is a much simpler DNA structure. It’s complete, but simpler in its form. It enables us to use a single cell line from a single donor to match very large numbers of people. So it gives us the potential a few years down the road to have a true stem cell bank. And by that I don’t mean the banking of somebody’s own cells, but a bank much like a blood bank in which any patient who needs stem cells can come, get cells that will match their immune system and thereby eliminate or reduce the need for immunosuppressant drugs.

We think ultimately that’s going to be the single defining differentiator for our company because a cell transplant is like a miniature organ transplant. If the body rejects it, there’s no benefit, and we’re working on a way to provide cells that anyone can use at any time for any disease that any scientist is smart enough to figure out a way to treat with cells. It’s a tall order but we think we’re up to it.

To read the full text or listen to the interview, please visit onemedplace -http://www.onemedplace.com/blog/archives/9031

International Stem Cell Corporation to Present at the Southern California Investor Conference on Monday, August 29th

2011-08-23T08:01:00.000-07:00

International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, will be presenting at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 1:30 p.m. Pacific (4:30 p.m. Eastern). The conference takes place at The Island Hotel in Newport Beach, California.

The Southern California Investor Conference is the only conference focused exclusively on the wealth of exciting growth companies from Southern California. The annual one-day conference features more than 35 companies from the region presenting to attendees from throughout the nation. The conference is open to the public and investors can find a list of 2011 presenting companies and registration information at www.CaliforniaStocks.com

A webcast of the International Stem Cell Corporation presentation will be accessible online at http://events.powerstream.net/002/00271/20110829_SCIC_T2/ or from the link on the Company's web site at www.internationalstemcell.com. An archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Part 4: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

2011-08-22T10:22:00.001-07:00

Ellis Martin of The Ellis Martin Report interviews Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease. http://www.ellismartinreport.com Contact: martinreports@gmail.com. International Stem Cell is a paid sponsor of The Ellis Martin Report

International Stem Cell Corp.: Mass Marketing Regenerative Medicine By Patrick Cox

2011-08-22T08:46:00.001-07:00

We thought you might like to see a recent article published by Patrick Cox. Patrick writes regular columns about microcap stocks, particularly in the biotech field. His columns can be subscribed to at http://breakthroughtechnologyalert.agorafinancial.com

Click HERE to view in Full Screen

International Stem Cell Corp.: Mass Marketing Regenerative Medicine By Patrick Cox

International Stem Cell's Q2 Revenues Nearly Triple by Deborah Sterescu

2011-08-19T10:51:00.000-07:00

International Stem Cell Corporation (ISCO) (OTCBB:ISCO) reported Wednesday that second quarter sales more than doubled to almost triple, while year-to-date sales jumped a whopping 271%, as the company's operating subsidiaries continue to generate more revenue.

In addition to its hugely potentially valuable stem cell therapy business, the company also two other operations that have reflected revenue growth in the meantime, including Lifeline Cell Technology, which sells its cell-culture products to researchers to grow human cells for pre-clinical research, and Lifeline Skin Care, which sells skin care products based on its parent's stem cell technology.

For the three months ending June 30, International Stem Cell saw revenues rise to $1.1 million, from $0.44 million a year earlier.

Year-to-date revenues totaled $2.6 million, versus $0.7 million for the same period in 2010, helped by a $1.7 million contribution from Lifeline Skin Care, and a $0.9 million addition from Lifeline Cell.

In the last quarter, Lifeline Cell gained over 200 new customers due to new product introductions and the development of distribution channels internationally, a strategy ISCO plans to continue.

Meanwhile, the company's skin care business is coming off a highly successful launch at the end of last year, exceeding its plans to sell 1,000 products, with 7,000 products sold initially. Lifeline Skin plans to aggressively kick start major marketing initiatives again in September.

While these two subsidiaries are busy chalking up revenues, ISCO, whose parthenogenetic stem cell technology can be used to derive pluripotent stem cells, meaning they can be transformed into any cell type in the body, has many important advantages at its fingertips.

Regenerative medicine is a market that is set to boom in the coming years, as more and more companies are developing therapies based on stem cell use. International Stem Cell's long-term goal is to be a universal supplier of stem cells for not just one, but a host of therapies.

The company's parthenogenetic stem cells are derived from unfertilized eggs, avoiding the ethical issues behind the destruction of viable human embryos. Like embryonic stem cells, they also have the capacity to become almost any cell type in the body, but have demonstrated they are better in terms of the immune system, as one single stem cell line can be genetically matched to millions of people, reducing the need for immunosuppressants.

Its plan is to establish a US bank of its clinical-grade human parthenogenetic stem cells that will be capable of being immune-matched to millions of patients, so that a physician could call up and request a specific cell type for people. The company, which recently received approvals to enroll around 3 US donors for its bank, already has a collection of ten human parthenogenetic stem cell lines used for research purposes, which were derived outside the US.

These cell lines could potentially be used to cure a number of diseases, including cancer, heart disease, liver disease, among many others. Already, the company has several trials in the works, and has successfully demonstrated in pre-clinical animal studies that its stem cells can be used to create viable liver cells. It has also started pre-clinical animal trials to create neuronal cells in the brain, to potentially cure Parkinson's disease.

Unsurprisingly, all this work to progress the company's technology has increased expenses, contributing to a $2.5 million loss in the second quarter, or a 3 cent loss per share.

Research and development costs grew on account of greater scientific projects, while general and administrative costs leapt on increased headcount as the company bulks up its management team.

International Stem Cell, with $3.6 million in the bank at the end of the quarter, said that it has not ruled out future capital raising, but it already has a facility that allows it to draw equity as necessary to secure its planned growth.